Astellas FY24 profits surge; confident outlook for FY25

** Astellas Pharma (TSE: 4503) announced a robust financial performance for the fiscal year ended March 31, 2025, achieving record revenues and core operating profits. Revenue surged 19.2% to JPY1,912.3 billion, driven by key products like XTANDI, PADCEV, and IZERVAY. Core operating profit jumped 41.7% to JPY392.4 billion due to strong sales and the company’s Sustainable Margin Transformation (SMT) initiative, which aims for JPY40.0 billion in cost optimization. A tax benefit of JPY20.6 billion stemming from the liquidation of Ganymed Pharmaceuticals GmbH boosted net profits.